Lauren Nye, MD
Internal Medicine · Westwood, KSNPI 1285953596
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Myriad Genetic Laboratories, Inc. accounts for 93.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $2,800 and has fallen 91.9% since, to $226 in 2025. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $434.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$6K
- Stemline Therapeutics Inc.$206
- Genentech USA, Inc.$67
- AstraZeneca$38
- Pfizer$25
- Caris MPI, Inc.$24
- plus $21 from 1 others
Across 17 payments — averaging $23,726 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$324K
- Amgen$80K
- Merck$42
What the payments were for
- Consulting fees$2,80046%
- Speaking & faculty fees$2,80046%
- Food & beverage$4778%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 5 | $5,696 |
| Stemline Therapeutics Inc. | 3 | $206 |
| Genentech USA, Inc. | 1 | $67 |
| AstraZeneca | 2 | $38 |
| Pfizer | 1 | $25 |
| Caris MPI, Inc. | 1 | $24 |
| Gilead | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myChoice CDx$2,800
- PreciseTumor$2,800
- Orserdu$121
How this compares
$6,077 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 21 | $307,761 |
| Anastrozole | 309 | $6,085 |
| Potassium Chloride | 11 | $2,286 |
| Raloxifene Hcl | 42 | $2,228 |
| Exemestane | 21 | $1,845 |
| Letrozole | 70 | $1,677 |
| Gabapentin | 39 | $496 |
| Oxybutynin Chloride | 18 | $472 |
| Tamoxifen Citrate | 13 | $202 |
| Omeprazole | 32 | $127 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Westwood
- Raed Al RajabiWestwood$49K
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.